Audentes Therapeutics (BOLD) IPO Prices at $15, Middle of Range

Audentes Therapeutics (NASDAQ: BOLD) announced the pricing of its initial public offeringof 5,000,000 shares of its common stock at a price to the public of $15.00 per share, the middle of the expected $14.00-$16.00 range. The shares are expected to begin trading on The NASDAQ Global Market today under the symbol "BOLD." Trading is expected at approximately 10:25AM ET.

BofA Merrill Lynch, Cowen and Company and Piper Jaffray are acting as joint book-running managers for the offering. Wedbush PacGrow is acting as a co-manager.

Audentes is a biotechnology company focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. They believe that gene therapy has powerful potential to treat these diseases through delivery of a functional copy of the affected gene to cells, resulting in production of the normal protein. The company has built a compelling portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy, or XLMTM, AT342 for the treatment of Crigler-Najjar Syndrome, or Crigler-Najjar, AT982 for the treatment of Pompe disease and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia, or CASQ2-CPVT. Audentes plans to submit Investigational New Drug applications, or INDs, or Clinical Trial Authorisations, or CTAs, for AT982 in the third quarter of 2016, for AT342 in the fourth quarter of 2016 and for AT132 in the first quarter of 2017, and expect to have preliminary data from all three programs in the second half of 2017. Audentes maintains full global rights to all of their product candidates.

You May Also Be Interested In

• Marex Group (MRX) Opens At $19.50, IPO At $19
• Tungray Technologies (TRSG) Closes $5M IPO
• Veg House Holdings (VEG) Announces 1M Share IPO at $5/sh